Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia - Wikidata - wikimedia - TriplyDB

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

http://www.wikidata.org/entity/Q28217778

about

sameAs

Deferasirox for managing iron overload in people with myelodysplastic syndrome Deferasirox for managing transfusional iron overload in people with sickle cell disease Oral deferiprone for iron chelation in people with thalassaemia Deferasirox for managing iron overload in people with thalassaemia Deferasirox for managing transfusional iron overload in people with sickle cell disease Deferasirox for managing iron overload in people with myelodysplastic syndrome Deferasirox for managing iron overload in people with thalassaemia Deferasirox for managing iron overload in patients with myelodysplastic syndrome Deferasirox for managing transfusional iron overload in people with sickle cell disease Oral deferiprone for iron chelation in people with thalassaemia Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia Thalassaemia major: the murky story of deferiprone Evaluation of liver fibrosis: "Something old, something new…"Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study.Quantitative assessment of iron in heart and liver phantoms using dual-energy computed tomography.Discordance between liver biopsy and Fibroscan® in assessing liver fibrosis in chronic hepatitis b: risk factors and influence of necroinflammation.Pharmacotherapy of iron overload in thalassaemic patients.Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.Reductions in post-hepatectomy liver failure and related mortality after implementation of the LiMAx algorithm in preoperative work-up: a single-centre analysis of 1170 hepatectomies of one or more segments.Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection Thalassemia and related hemoglobinopathies.Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective Light and shadows in the iron chelation treatment of haematological diseases.Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy.Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias.Pattern and profile of chronic liver disease in acute on chronic liver failure.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Deferasirox for managing iron overload in people with thalassaemia.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Deferiprone for the treatment of transfusional iron overload in thalassemia.Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.Safety profiles of iron chelators in young patients with haemoglobinopathies.Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan.Systematic quantification of histological patterns shows accuracy in reflecting cirrhotic remodeling.Development and Validation of a Terbium-Sensitized LuminescenceAnalytical Method for Deferiprone.Histological subclassification of cirrhosis can predict recurrence after curative resection of hepatocellular carcinoma.Five-year trial of deferiprone chelation therapy in thalassaemia major patients.Glutamine synthetase expression in activated hepatocyte progenitor cells and loss of hepatocellular expression in congestion and cirrhosis.

P2860

Q24193067-C593C081-90FC-4A8D-9970-64288F02970E Q24194549-60497FBF-6854-471A-B96E-6E4772A53A78 Q24200309-8BEF9E4C-2E14-422B-810B-726E66E22355 Q24203718-5A0FC525-8852-42B4-B94F-7A3216D15CF0 Q24236463-C227D1AD-FBD2-4D57-B68E-587EE9B8B2FE Q24236532-247F5EEA-28AF-479A-A85A-BF6D2527F411 Q24241753-F0C1DFF6-D9CF-45D1-B90D-5C7C9E3BE77F Q24242437-5CF3EC05-0ADE-4BD0-AAAB-3E41C0E54917 Q24242535-571DA7C5-8145-4814-A85A-7240FAC722F8 Q24244045-FA91B8B7-7374-4C22-A915-D3A2F07B8A0B Q24245574-D0E1D739-0A83-429A-BB84-71DF21605A10 Q24621999-B648D300-E13D-42F4-8FA4-CF47041A4DCE Q28068532-789CEA72-7D3B-431B-B0CE-B227B4222CD0 Q33407282-32D60F10-6F84-4A19-9943-EF26583BEB1A Q33629906-989A6603-A3C4-4C0B-A190-0BD1D97BF467 Q33962247-86253DD1-4F42-454B-A7BF-1F9BE06FEABD Q34182393-F4FCE6A5-F157-4E5B-B3C0-A3C3106A74AA Q35548173-54706932-ECC2-4230-A05A-5A5AFF09EC48 Q35657936-D7E7D504-C615-4393-BDC3-182149E70057 Q35683841-D10CD02A-81A5-4D66-8CB8-F858AD8884B4 Q35761124-F11176C0-947D-43D5-82E6-96517D9F0372 Q35929511-6288ABC6-C94A-4A7E-A293-E6558A3B9259 Q36117787-66B2B3D9-EB1E-4E56-B1F2-4D660291DB43 Q36645815-7A604A60-61C4-44BE-B35F-34F4D76D2355 Q36894343-FF134F25-52F7-4264-9F48-98F6EDD861DC Q37092252-FFBD4444-9BD9-4F96-8837-165B7AA0897E Q37880227-F025AA34-0522-4000-B083-36F39B42B6E0 Q38504279-5452266A-5566-4444-8D02-0EAD7089FE60 Q38540491-566BD784-8796-4C65-9C1A-D86D7E888BBA Q38624033-A4E35EA4-76E8-449F-BE12-41A43782A404 Q38650293-767E43B8-1DB3-44CE-BAED-82CD0DEB3F45 Q38817259-72058845-8EB6-46CD-9E4C-9227985E27FB Q38962101-9866E0A7-E979-4921-9599-2A8CEA13699D Q39022073-B0BDAD7F-A778-44F3-82BB-E7A2CF667276 Q39215441-C4F99D05-BA3D-4C9C-8CD9-7BCC8FED33BC Q40379402-D8B5B7F7-C2AE-4D60-9368-02CBF17198E8 Q42078143-646F2D61-D697-4CA4-B028-D1199F28832E Q42239805-6AB66ECD-0F6A-454A-A2DE-E48F9F5AF3E5 Q42989110-E573BBEF-73F0-4700-966F-B4D174FF07B8 Q43499973-69B36D2F-9050-48F8-8BF7-7EA4B4E04230

P2860

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia

http://www.wikidata.org/entity/Q28217778

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@ast

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@en

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@nl

type

label

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@ast

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@en

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@nl

prefLabel

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@ast

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@en

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@nl

P1433

Q28217778-629F2D88-77AB-45AC-A6AC-570974D05D03

P1476

Q28217778-0004B277-25A9-4851-ACB8-293D4ECF0AA6

P2093

Q28217778-05CC3EA4-2A14-481B-8322-F53753DC76ED

Q28217778-23FCCAF8-33A5-4B93-B3D1-628E6E50D795

Q28217778-258AB4CB-6943-4849-B71F-02CD5FC89ED3

Q28217778-428D67D2-B2C3-4AAB-82D0-7D720772896C

Q28217778-8B3DBB81-B234-43EE-B892-68E29A639E34

Q28217778-96321A14-6DEF-4707-B047-BA8D7880045C

Q28217778-9C2C3C48-889B-46D9-AFF4-73EC37E439F9

Q28217778-C6D1E70B-936D-4A9E-902D-8AFD77E61670

Q28217778-F318D268-E295-4CEB-85A4-D9CA23DE8339

P304

Q28217778-73B8559C-35D6-484A-91DD-A8D054F08662

P31

Q28217778-A47B4351-B921-48DE-BC68-BE66089DAEBE

P3181

Q28217778-17D864EE-B6D0-4941-94C7-9CFCA23DA04A

P356

Q28217778-DC4264EF-193A-4D4A-9941-7092CB48E403

P407

Q28217778-7D57065D-3F2D-4B7D-B81E-06C9BCAB64ED

P433

Q28217778-6E4291AE-454E-42DD-9033-5BA6264CB8D6

P478

Q28217778-CBD8B901-3A34-4951-A00E-F3065D9F7929

P577

Q28217778-E868F997-441C-4038-91B2-41C76CE0D682

P5875

Q28217778-9F526EB9-953B-426D-9B60-601F3D50D17B

P698

Q28217778-7021E9B8-8237-499A-9C9D-1CB751128347

P3181

P356

BLOOD-2002-01-0306

P1433

P1476

Lack of progressive hepatic fi ...... ion-dependent beta-thalassemia

@en

P2093

Alan R Cohen

http://www.w3.org/2001/XMLSchema#string

Amar P Dhillon

http://www.w3.org/2001/XMLSchema#string

Antonio Piga

http://www.w3.org/2001/XMLSchema#string

Elias Schwartz

http://www.w3.org/2001/XMLSchema#string

George Sweeney

http://www.w3.org/2001/XMLSchema#string

Ian R Wanless

http://www.w3.org/2001/XMLSchema#string

M Rita Gamberini

http://www.w3.org/2001/XMLSchema#string

Maria Guido

http://www.w3.org/2001/XMLSchema#string

Renzo Galanello

http://www.w3.org/2001/XMLSchema#string

P304

1566-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4814383

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2002-01-0306

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11210150

http://www.w3.org/2001/XMLSchema#string

P698

12176871

http://www.w3.org/2001/XMLSchema#string